+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bromodomain Testis Specific Protein - Pipeline Review, H2 2020

  • ID: 5174746
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 57 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Ningbo Wenda Pharma
  • Zenith Epigenetics Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Phase II and Phase I stages are 2 and 3 respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Lymphoma, Melanoma, Myelofibrosis, Myeloproliferative Disorders, Non-Hodgkin Lymphoma, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Pancreatic Cancer, Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor and Unspecified B-Cell Lymphomas.

The latest report Bromodomain Testis Specific Protein - Pipeline Review, H2 2020, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
  • The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Ningbo Wenda Pharma
  • Zenith Epigenetics Ltd
Introduction
  • Report Coverage
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • Ningbo Wenda Pharma
  • Zenith Epigenetics Ltd
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles

BI-894999 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CC-95775 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CPI-0610 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NHWD-870 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ZEN-3694 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Dormant Products

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
  • Featured News & Press Releases
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Actavalon Inc, H2 2020
  • Pipeline by Active Biotech AB, H2 2020
  • Pipeline by Ampio Pharmaceuticals Inc, H2 2020
  • Pipeline by AnTolRx Inc, H2 2020
  • Pipeline by Bayer AG, H2 2020
  • Pipeline by Dermavant Sciences Inc, H2 2020
  • Pipeline by Hercules Pharmaceuticals BV, H2 2020
  • Pipeline by Hutchison MediPharma Ltd, H2 2020
  • Pipeline by Ikena Oncology Inc, H2 2020
  • Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
  • Pipeline by Magenta Therapeutics Inc, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Phenex Pharmaceuticals AG, H2 2020
  • Pipeline by Shenogen Pharma Group Ltd, H2 2020
  • Pipeline by Sol-Gel Technologies Ltd, H2 2020
  • Pipeline by Welichem Biotech Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • Ningbo Wenda Pharma
  • Zenith Epigenetics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll